Clinical analysis of vitreous resection combined with vitrectomy combined with vitrectomy for proliferative diabetic retinopathy
Objective To investigate the clinical effect of vitrectomy with single slice vitrectomy (PDR) and preoperative injection of monoclonal antibody (mAb) for treatment of proliferative diabetic retinopathy. Methods According to clinical treatment were randomly 64 cases of PDR patients in our hospital in February 2016-February 2017 were divided into observation group and control group, 32 cases (37 eyes) single vitreous body resection were included in the control group, the remaining 32 cases (41 eyes) from preoperative intravitreal injection 0.5mg Lei Zhu monoclonal antibody drug treatment after resection of vitreous body were included in the observation group. The operation time, the best corrected visual acuity before and after the operation were recorded and compared between the two groups. The incidence of iatrogenic hiatus, frequency use, vitreous volume and hyphema were recorded in the two groups. Results The operation time of the observation group was (96.47±12.67) min, which was significantly shorter than that of the control group (128.56±13.78) min (P<0.05). The best corrected visual acuity of the two groups was basically at the same baseline level, and the corrected visual acuity of the 30d observation group was obviously improved and better than that of the control group (P<0.05). Compared with the control group, the incidence of iatrogenic hiatus, electrocoagulation, vitreous volume and hyphema was lower in the observation group (P<0.05). Conclusion Intravitreal injection of ranibizumab therapy after resection of vitreous body regimen in the treatment of PDR is safe and effective, not only helps to shorten the operation time, and lower incidence of postoperative complications, postoperative recovery of visual acuity is good, it is worthy of clinical popularization and wide application of bed.
NETL
NSTL
万方数据
维普
